rc 3095 has been researched along with dacarbazine in 1 studies
| Studies (rc 3095) | Trials (rc 3095) | Recent Studies (post-2010) (rc 3095) | Studies (dacarbazine) | Trials (dacarbazine) | Recent Studies (post-2010) (dacarbazine) |
|---|---|---|---|---|---|
| 108 | 2 | 26 | 7,556 | 1,463 | 3,429 |
| Protein | Taxonomy | rc 3095 (IC50) | dacarbazine (IC50) |
|---|---|---|---|
| Matrix metalloproteinase-9 | Homo sapiens (human) | 0.556 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Battastini, AM; Braganhol, E; Brunetto, AL; Cechim, G; de Castro, CG; de Oliveira, MS; Lenz, G; Meurer, L; Roesler, R; Santos, DG; Schwarstmann, G; Schwartsmann, G | 1 |
1 other study(ies) available for rc 3095 and dacarbazine
| Article | Year |
|---|---|
Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bombesin; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell Survival; Dacarbazine; Exploratory Behavior; Flow Cytometry; Glioblastoma; Male; Peptide Fragments; Rats; Rats, Wistar; Receptors, Bombesin; Temozolomide | 2009 |